4.72
전일 마감가:
$5.10
열려 있는:
$5.08
하루 거래량:
3.08M
Relative Volume:
1.17
시가총액:
$1.60B
수익:
$9.47B
순이익/손실:
$-178.00M
주가수익비율:
-9.8333
EPS:
-0.48
순현금흐름:
$1.01B
1주 성능:
+8.76%
1개월 성능:
-34.08%
6개월 성능:
-42.23%
1년 성능:
-45.68%
Bausch Health Companies Inc Stock (BHC) Company Profile
명칭
Bausch Health Companies Inc
전화
514-744-6792
주소
2150 ST. ELZEAR BLVD. WEST, QUEBEC, QC
BHC을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
BHC
Bausch Health Companies Inc
|
4.72 | 1.60B | 9.47B | -178.00M | 1.01B | -0.48 |
![]()
ZTS
Zoetis Inc
|
146.85 | 67.28B | 9.26B | 2.49B | 2.30B | 5.47 |
![]()
HLN
Haleon Plc Adr
|
10.19 | 45.61B | 14.35B | 1.85B | 0 | 0.4023 |
![]()
TAK
Takeda Pharmaceutical Co Adr
|
14.93 | 45.01B | 30.25B | 1.37B | 5.08B | 0.4257 |
![]()
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
13.31 | 15.25B | 16.54B | -1.64B | 749.00M | -1.45 |
![]()
UTHR
United Therapeutics Corp
|
284.25 | 12.77B | 2.76B | 1.11B | 898.10M | 22.77 |
Bausch Health Companies Inc Stock (BHC) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2024-08-02 | 다운그레이드 | Piper Sandler | Neutral → Underweight |
2024-07-10 | 개시 | Raymond James | Mkt Perform |
2023-09-20 | 업그레이드 | Jefferies | Hold → Buy |
2023-06-16 | 다운그레이드 | TD Cowen | Outperform → Market Perform |
2022-07-29 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
2022-07-29 | 다운그레이드 | Truist | Buy → Hold |
2022-07-28 | 다운그레이드 | JP Morgan | Overweight → Neutral |
2022-06-13 | 재개 | JP Morgan | Overweight |
2021-03-24 | 다운그레이드 | BofA Securities | Neutral → Underperform |
2021-02-17 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
2021-01-22 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
2020-09-17 | 업그레이드 | BofA Securities | Underperform → Neutral |
2020-08-24 | 재확인 | H.C. Wainwright | Buy |
2020-06-17 | 재확인 | H.C. Wainwright | Buy |
2020-04-24 | 개시 | Citigroup | Buy |
2020-04-02 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
2020-01-29 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
2020-01-22 | 업그레이드 | Wells Fargo | Underweight → Equal Weight |
2019-12-12 | 업그레이드 | JP Morgan | Neutral → Overweight |
2019-12-02 | 개시 | Goldman | Neutral |
2019-10-25 | 개시 | Cowen | Outperform |
2019-09-12 | 개시 | Guggenheim | Buy |
2019-08-15 | 업그레이드 | TD Securities | Hold → Buy |
2019-07-19 | 개시 | Wolfe Research | Outperform |
2019-06-11 | 재개 | Barclays | Overweight |
2019-05-13 | 업그레이드 | JP Morgan | Underweight → Neutral |
2019-03-20 | 개시 | SunTrust | Buy |
2019-01-02 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
2018-11-05 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
2018-09-13 | 업그레이드 | Piper Jaffray | Underweight → Neutral |
모두보기
Bausch Health Companies Inc 주식(BHC)의 최신 뉴스
Bausch Health stock jumps after Carl Icahn stake (BHC:NYSE) - Seeking Alpha
Bausch Health updates proxy statement on Icahn’s interest - Investing.com
Bausch Health Addresses Icahn’s Equity Swaps and Adopts Shareholder Rights Plan - TipRanks
Bausch Health shares surge on Icahn’s significant economic interest - Investing.com
Bausch Health Brief: Filing Supplement In Response to Co Learning that Carl Icahn and Affiliates Have Cash-Settled Equity Swaps for Approximately 90 Million of Its Common Shares - marketscreener.com
Bausch Health Announces Filing of Supplement to Proxy Statement - standard-journal.com
Press Release Distribution & PR Platform - ACCESS Newswire
Carl Icahn's Secret 34% Bausch Health Stake Triggers Defensive Poison Pill Response - Stock Titan
April 2025's Top Growth Stocks With Strong Insider Ownership - simplywall.st
BofA Cuts Price Target on Bausch Health to $5 From $7 - marketscreener.com
TSX falls as Trump's Fed criticism shakes markets - marketscreener.com
Bausch (BHC) Moves 13.3% Higher: Will This Strength Last? - Nasdaq
Analysts Expect Bausch Health Companies Inc. (NYSE:BHC) To Breakeven Soon - simplywall.st
Is Bausch Health Companies (BHC) the Ridiculously Cheap Stock to Invest in? - Yahoo Finance
11 Ridiculously Cheap Stocks to Invest in - Insider Monkey
Bausch Health Provides Update on Solta Medical - marketscreener.com
U.S. District Court Rules in Favor of Bausch Health and FDA in XIFAXAN Case - TipRanks
Bausch Health shares jump on favorable court ruling By Investing.com - Investing.com South Africa
Bausch Health shares jump on favorable court ruling - Investing.com
Bausch says court grants summary judgment in favor of FDA, Salix, and Teva - TipRanks
Major Legal Win: How Bausch Health's Court Victory Protects Billion-Dollar XIFAXAN Franchise Until 2028 - Stock Titan
Fitch raises Bausch Health rating to CCC+ amid refinancing By Investing.com - Investing.com Canada
Fitch raises Bausch Health rating to CCC+ amid refinancing - Investing.com
Fitch Upgrades Bausch + Lomb, Bausch Health But Keeps Both Junk - Bloomberg.com
Topical Drug Delivery Market Set to Witness Significant Growth - openPR.com
Verteporfin Market Generated Opportunities, Future Scope - openPR.com
Bausch Health Companies IncAdopts Shareholder Rights PlanSEC Filing - marketscreener.com
Scar Treatment Market Set to Witness Significant Growth - openPR.com
Bausch Health Adopts Shareholder Rights Plan to Ensure Fair Treatment - TipRanks
Bausch Health Announces Adoption of Shareholder Rights Plan - The Joplin Globe
Bausch Health's New Poison Pill Defense: Key Details of Shareholder Protection Strategy - Stock Titan
The most oversold and overbought stocks on the TSX - The Globe and Mail
Bausch Health Responds to Norwich Pharmaceuticals Tentative FDA Approval for a 200 mg Rifaximin - marketscreener.com
Intraocular Lens Market Overall Study Report 2025-2032 | Bausch - openPR.com
Bausch Health Announces Ortho Dermatologics 2025 ASPIRE HIGHER Scholarship Program - ACCESS Newswire
New $10K Scholarship Program Empowers Students Affected by Skin Conditions - Stock Titan
Bausch Health secures intent for acne treatment coverage By Investing.com - Investing.com South Africa
Atopic Dermatitis Pipeline 2025: Therapies Under - openPR.com
Bausch Health signs LOI with pan-Canadian Pharmaceutical Alliance for CABTREO - TipRanks
Bausch Health Canada signs Cabtreo public drug plan coverage letter of intent - TipRanks
Bausch Health secures intent for acne treatment coverage - Investing.com Australia
Bausch Health, Canada Inc. and the pan-Canadian Pharmaceutical Alliance Sign Letter of Intent for Public Drug Plan Coverage of (Pr)CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide gel) Treatment for Acne Vulgaris - Yahoo Finance
Bausch Health Companies Unit Entered Into A New Senior Secured Credit Agreement - MarketScreener
First-Ever Triple-Action Acne Treatment Now Covered by Canadian Public Drug Plans - Stock Titan
Ophthalmology Market Report 2025 | Industry to Reach US$93.7 Billion by 2030 | Emerging Research Activities of Ophthalmology Treatments and Availability of Grants Present Business Opportunities - GlobeNewswire Inc.
Bausch Health Misses Revenue Estimates, RBC Analysts React - Finimize
Bausch Health Faces Revenue Miss And Price Target Cut - Finimize
Alex Meruelo Reports 9.99% Stake In Bausch Health Companies Inc As Of March 31SEC Filing - MarketScreener
Sector Update: Health Care Stocks Slipping in Late Afternoon Trading - MarketScreener
Bausch Health Faces Challenges Amid Price Target Downgrade - Evrim Ağacı
Bausch Health stock target cut to $8.50 by RBC Capital - Investing.com South Africa
Bausch Health Companies Inc (BHC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):